Oct 112017

This image depicts the structure of the BAX protein (purple). The activator compound BTSA1 (orange) has bound to the active site of BAX (green), changing the shape of the BAX molecule at several points (shown in yellow, magenta and cyan). BAX, once in its final activated form, can home in on mitochondria and puncture their outer membranes, triggering apoptosis (cell death).

Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers.

“We’re hopeful that the targeted compounds we’re developing will prove more effective than current anti-cancer therapies by directly causing cancer cells to self-destruct,” says Evripidis Gavathiotis, Ph.D., associate professor of biochemistry and of medicine and senior author of the study. “Ideally, our compounds would be combined with other treatments to kill cancer cells faster and more efficiently—and with fewer adverse effects, which are an all-too-common problem with standard chemotherapies.”

AML accounts for nearly one-third of all new leukemia cases and kills more than 10,000 Americans each year. The survival rate for patients has remained at about 30 percent for several decades, so better treatments are urgently needed.

The newly discovered compound combats cancer by triggering apoptosis—an important process that rids the body of unwanted or malfunctioning cells. Apoptosis trims excess tissue during embryonic development, for example, and some chemotherapy drugs indirectly induce apoptosis by damaging DNA in cancer cells.

Apoptosis occurs when BAX—the “executioner protein” in cells—is activated by “pro-apoptotic” proteins in the cell. Once activated, BAX molecules home in on and punch lethal holes in mitochondria, the parts of cells that produce energy. But all too often, cancer cells manage to prevent BAX from killing them. They ensure their survival by producing copious amounts of “anti-apoptotic” proteins that suppress BAX and the proteins that activate it.

“Our novel compound revives suppressed BAX molecules in cancer cells by binding with high affinity to BAX’s activation site,” says Dr. Gavathiotis. “BAX can then swing into action, killing cancer cells while leaving healthy cells unscathed.”

Dr. Gavathiotis was the lead author of a 2008 paper in Nature that first described the structure and shape of BAX’s activation site. He has since looked for small molecules that can activate BAX strongly enough to overcome cancer cells’ resistance to apoptosis. His team initially used computers to screen more than one million compounds to reveal those with BAX-binding potential. The most promising 500 compounds—many of them newly synthesized by Dr. Gavathiotis’ team—were then evaluated in the laboratory.

“A compound dubbed BTSA1 (short for BAX Trigger Site Activator 1) proved to be the most potent BAX activator, causing rapid and extensive apoptosis when added to several different human AML cell lines,” says lead author Denis Reyna, M.S., a doctoral student in Dr. Gavathiotis’ lab. The researchers next tested BTSA1 in blood samples from patients with high-risk AML. Strikingly, BTSA1 induced apoptosis in the patients’ AML cells but did not affect patients’ healthy blood-forming stem cells.

Finally, the researchers generated animal models of AML by grafting human AML cells into mice. BTSA1 was given to half the AML mice while the other half served as controls. On average, the BTSA1-treated mice survived significantly longer (55 days) than the control mice (40 days), with 43 percent of BTSA1-treated AML mice alive after 60 days and showing no signs of AML.

Importantly, the mice treated with BTSA1 showed no evidence of toxicity. “BTSA1 activates BAX and causes apoptosis in AML cells while sparing healthy cells and tissues—probably because the cancer cells are primed for apoptosis,” says Dr. Gavathiotis. He notes that his study found that AML cells from patients contained significantly higher BAX levels compared with normal blood cells from healthy people. “With more BAX available in AML cells,” he explained, “even low BTSA1 doses will trigger enough BAX activation to cause apoptotic death, while sparing healthy cells that contain low levels of BAX or none at all.”

Plans call for Dr. Gavathiotis and his team to see whether BTSA1 will show similar effectiveness when tested on animal models of other types of cancer.

Learn more: Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells


The Latest on: Cancer cells commit suicide
  • Suicide molecules: Combatting cancer in a unique manner
    on October 22, 2017 at 8:44 pm

    A team of researchers has recently found a ‘suicide molecule ... protect us from cancer. Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports ... […]

  • Novel compound causes cancer to self-destruct
    on October 10, 2017 at 7:47 am

    Scientists have discovered the first compound that directly drives cancer cells to commit suicide while sparing healthy cells, paving the way for faster and more efficient treatments with fewer side effects. The new treatment approach developed by ... […]

  • New compound can make cancer cells commit suicide
    on October 10, 2017 at 1:19 am

    Researchers say that this compound can be very useful for a country like India, which is seeing a growth in cancer cases. Washington: A group of researchers has found a compound which can kill cancer cells without harming the healthy cells present in our ... […]

  • Novel therapy drives cancer cells to commit suicide
    on October 9, 2017 at 11:40 pm

    New York, Oct 10 (IANS) Scientists have discovered a compound that directly makes cancer cells commit suicide while sparing healthy cells, paving the way for a more effective cancer treatment with fewer adverse effects. "We're hopeful that the targeted ... […]

  • Cancer commits suicide 'in just 2 hours'
    on July 4, 2016 at 1:21 pm

    (THE SUN) — Cancer cells in lab mice were found to self-destruct ... “The one thing they have in common is their susceptibility to this induced cell suicide. […]

  • Magnetic Nanoparticles Target Tumors and Get Cells to Commit Suicide
    on August 22, 2014 at 5:50 am

    the liver tumor promoter gene “drives” the nanoparticle to the liver cancer cells and then the suicide gene causes the cancer cells to commit suicide. These nanoparticles were about 20 nm wide, do not provoke an immune system response and they can be ... […]

  • This Single Molecule Drives Cancer Cells to Suicide
    on February 8, 2013 at 12:56 am

    A team of researchers has identified a single molecule, called TIC10, that kick-starts the body's tumor-destroying systems—causing a chain reaction that can kill cancer dead ... which causes cancerous cells to commit suicide. Wafik El-Deiry, one of ... […]

  • Cancer's Nemesis: The Suicide Gene
    on September 13, 1997 at 5:00 pm

    If you mutate P-53, you deprive the cell of even that last refuge." The idea that cancer cells disobey their normal genetic instructions to commit suicide is so new it is just beginning to trickle into medical schools. "We're entering a whole new phase of ... […]

via Google News and Bing News

Other Interesting Posts

Leave a Reply

%d bloggers like this: